0001209191-23-002979.txt : 20230111 0001209191-23-002979.hdr.sgml : 20230111 20230111160938 ACCESSION NUMBER: 0001209191-23-002979 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230110 FILED AS OF DATE: 20230111 DATE AS OF CHANGE: 20230111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wolchko J Scott CENTRAL INDEX KEY: 0001586893 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36076 FILM NUMBER: 23523687 MAIL ADDRESS: STREET 1: C/O FATE THERAPEUTICS, INC. STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FATE THERAPEUTICS INC CENTRAL INDEX KEY: 0001434316 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 651311552 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 BUSINESS PHONE: 858.875.1803 MAIL ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-10 0 0001434316 FATE THERAPEUTICS INC FATE 0001586893 Wolchko J Scott C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 1 1 0 0 President and CEO Common Stock 2023-01-10 4 S 0 45907 5.24 D 385639 D Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 62,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 7, 2019, 16,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, and 10,808 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. Represents the weighted average sale price of the shares sold ranging from $5.11 to $5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. /s/ Cindy Tahl, as Attorney-in-Fact 2023-01-11